David Sylvain

Posts Tagged 'hollywood boutique'

Micron Earnings: Memory-chip Demand Has Pushed Stock To Highest Prices Since Dot-com Boom – MarketWatch

Daily Finan. Bull 3X Shs(ETF)(FAS) – FAS trendy boutique continues to show strength after a nice three day bounce off the $7.93 lows. I picked some sample stocks and ETFs to predict stock prices in December 2020. I used daily stock closing price from January 1st, 2016 to December 31st, 2019 to forecast closing prices for the entire year. Micron forecast 69 cents to 73 cents a share back in December, up from the 40 cents to 54 cents a share the company forecast in its last earnings report. Net income for the quarter to Nov. 29 fell to $96.0 million, or 73 cents a share, from $24.7 million, or 20 cents a share, in the year-ago period. Cell Therapeutics, Inc. (CTIC) – CTIC right now is dead money, not going up much, not going down much. This is what I am waiting for right now. I am waiting to get back in CTIC stock when the volume comes back. Hemispherx Biopharma, Inc. (HEB) – Still waiting on an FDA decision out of HEB for CFS drug Ampligen – HEB traded back above $2 for some of the day on Wednesday.


Ford Motor Company (F) – Ford traded down to $5.21 on Tuesday, almost near my buy price of $5. These big guys who have millions of dollars to invest usually represent a large part of the demand in the stock market because they need to buy so many shares with that amount of money. The stock Market Futures were actually down this morning but again, the fall in Libor Rates turned futures around in pre market. Hemispherx Biopharma, Inc. (HEB) – Shares of HEB were crushed on Tuesday morning as another big investor sold shares. Hemispherx Biopharma, Inc. (HEB) – Investors continue to wait for an FDA Approval Decision on a CFS drug called Ampligen. This could have been the capitulation selling investors were looking for and C stock could be gearing up for a run back to $3.25-$3.50 before earnings. I continue to have no position in the stock but am eagerly awaiting the FDA decision on Ampligen.